Photo from academic.microsoft.com
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide… Click to show full abstract
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.
Keywords:
bacillus calmette;
shortage;
manufacturing market;
calmette rin
Journal Title: European urology focus
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European urology focus
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!